Stoyan A. Radkov, PhD
As an undergraduate, Dr Radkov studied Microbiology graduating in 1995 with the highest 1st Class BSc Honours degree in Microbiology at the Faculty of Animal & Microbial Sciences, University of Reading – awarded The Abbott Laboratories Prize for academic excellence. Dr Radkov attained a PhD in Viral Oncology from the Ludwig Institute for Cancer Research, St Mary’s Hospital – Imperial College London and was a Cancer Research Campaign (CRC) funded Senior Research Fellow at Imperial College London and University College London. His scientific findings were published in J. Virology and Nature Medicine.
After a successful career as a senior scientist at Imperial College London and University College London, researching in viral oncology, Dr Radkov trained as a biotech & pharmaceuticals patent attorney at top tier IP firm D Young & Co in England, before moving in-house to Pfizer, Sandwich, England and then Novartis and Syngenta, in Switzerland.
A few of Dr. Radkov’s publications are provided below.
2000 NATURE MEDICINE: The Latent Nuclear Antigen of Kaposi’s sarcoma associated herpes virus targets the retinoblastoma-E2F pathway and with the oncogene H-ras transforms primary rat cells.
1999 JOURNAL OF VIROLOGY: Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription
1997 JOURNAL OF VIROLOGY: Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21.